Prostaglandin F2-alpha receptor

Description:

Description
  • Accession: P43088
  • Swissprot: PF2R_HUMAN
  • Organism: Homo sapiens
  • Gene: PTGFR
  • Target class: GPCR

Drug Relations:

bimatoprost
A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. Bioactivity details MOA
carboprost
A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of PREGNANCY. Bioactivity details MOA
dinoprost
A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions. Bioactivity details MOA
latanoprost
A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA. Bioactivity details MOA
latanoprostene bunod
Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss. Bioactivity details MOA
tafluprost
a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow Bioactivity details MOA
travoprost
A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. Bioactivity details MOA
cicaprost
Bioactivity details MOA
dinoprostone
The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. Bioactivity details MOA
enprostil
A synthetic PGE2 analog that has an inhibitory effect on gastric acid secretion, a mucoprotective effect, and a postprandial lowering effect on gastrin. It has been shown to be efficient and safe in the treatment of gastroduodenal ulcers. Bioactivity details MOA
iloprost
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation. Bioactivity details MOA
laropiprant
a potent orally active human prostaglandin D(2) receptor 1 antagonist Bioactivity details MOA
misoprostol
A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties. Bioactivity details MOA
sulprostone
Bioactivity details MOA